ARTICLE | Clinical News

ABT-450: Additional Phase II data

April 23, 2012 7:00 AM UTC

Additional data from the open-label, U.S. Phase II PILOT (Study M12-267) trial showed that 9 of 11 treatment-naive patients with HCV genotype 1 infection who received once-daily 150 mg ABT-450 plus ritonavir, ribavirin and ABT-072 for 12 weeks without interferon achieved an SVR 36 weeks after the end of treatment. Abbott said that of the 2 patients who relapsed, 1 relapsed at 8 weeks post-treatment and the other at 36 weeks post-treatment. Data were presented at the European Association for the Study of the Liver meeting in Barcelona. ...